CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $22.20.
CBLL has been the subject of several recent research reports. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. Canaccord Genuity Group reduced their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th.
Get Our Latest Analysis on CeriBell
CeriBell Stock Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. Analysts predict that CeriBell will post -1.69 earnings per share for the current fiscal year.
Insider Activity at CeriBell
In other CeriBell news, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $20.10, for a total value of $783,900.00. Following the sale, the chief executive officer owned 836,347 shares in the company, valued at $16,810,574.70. This represents a 4.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total value of $206,238.72. Following the completion of the sale, the chief technology officer owned 166,912 shares in the company, valued at $3,097,886.72. This represents a 6.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 112,826 shares of company stock valued at $2,162,374 over the last three months. Insiders own 20.10% of the company’s stock.
Institutional Trading of CeriBell
Several institutional investors and hedge funds have recently bought and sold shares of CBLL. JPMorgan Chase & Co. raised its stake in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares during the period. Rhumbline Advisers raised its stake in CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund raised its stake in CeriBell by 148.6% in the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares during the period. Quantbot Technologies LP raised its stake in CeriBell by 70.3% in the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after buying an additional 6,401 shares during the period. Finally, Invesco Ltd. bought a new stake in CeriBell in the second quarter valued at approximately $197,000.
CeriBell Company Profile
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
- Five stocks we like better than CeriBell
- Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
